Avadel Pharmaceuticals plc (AVDL)

In August 2025, Avadel exceeded expectations and raised its revenue guidance for the full year. In September 2025, new data on LUMRYZ was presented at World Sleep 2025. In October 2025, Avadel settled with Jazz Pharmaceuticals and was acquired by Alkermes plc for $1.8 billion. In November 2025, H. Lundbeck A/S submitted a non-binding proposal to acquire Avadel for $2.1 billion. Avadel reported earnings on November 4, 2025, with shares gaining 0.3% the following day. In December 2025, the company completed enrollment in its Phase 3 REVITALYZ™ Trial. In January 2026, shareholders approved the acquisition by Alkermes. As of February 2, 2026, revenue increased by 55.0% year-over-year, but the company reported a negative net margin and return on equity. Analysts held a consensus "Hold" rating with an average price target of $18.86, while shares traded around $21.55. The stock experienced a substantial increase of 163.81% between February 4, 2025, and February 3, 2026.

There is no explicit information indicating demand seasonality for Avadel Pharmaceuticals Plc's products and services. The available data suggests a consistent and growing demand for LUMRYZ, with new patient starts outpacing competitors. The company anticipates net revenues between $265 million and $275 million for the full year 2025, indicating a robust growth trajectory. Revenue is projected to increase by 15.6% annually, with earnings expected to surge by 40.12% each year, and the company is forecast to achieve profitability within three years.

Avadel Pharmaceuticals Plc is a specialty pharmaceutical company focused on developing and commercializing branded pharmaceutical products in the United States. It operates within the Healthcare sector, utilizing proprietary drug delivery technologies. Its flagship product is LUMRYZ, an extended-release formulation of sodium oxybate for treating cataplexy or excessive daytime sleepiness in adults and pediatrics with narcolepsy. The company is also conducting a Phase 3 clinical trial for LUMRYZ in Idiopathic Hypersomnia.

Avadel Pharmaceuticals Plc is incorporated in Ireland with its headquarters in Dublin. The company primarily focuses on the development and commercialization of its products in the United States. Avadel maintains operations and employs staff across the U.S. and internationally.

Avadel Pharmaceuticals has cultivated a strong brand reputation as an innovator in the sleep medicine sector. The company has successfully established and scaled a commercial organization that has driven significant demand for LUMRYZ since its launch in 2023. The proposed acquisition by Alkermes plc and the prior non-binding proposal from H. Lundbeck A/S underscore the company's perceived value and positive standing in the biopharmaceutical market.

Avadel Pharmaceuticals plc has 223 institutional owners and shareholders, holding a total of 85,901,929 shares. Major institutional owners include Janus Henderson Group Plc, BlackRock, Inc., Vanguard Group Inc, Brandes Investment Partners, Lp, Two Seas Capital LP, Gendell Jeffrey L, Polar Capital Holdings Plc, VTSMX - Vanguard Total Stock Market Index Fund Investor Shares, Vivo Capital, LLC, and JAGLX - Janus Henderson Global Life Sciences Fund Class T. Approximately 0.24% of the company's stock is held by institutional investors, 1.06% by insiders, and 74.91% by retail investors. Charles Brandes owns the most shares of Avadel Pharmaceuticals.